Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients
- PMID: 17709227
- DOI: 10.1016/j.ejso.2007.06.006
Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients
Abstract
Objective: To evaluate the impact of surgery as first-line treatment on event-free survival (EFS) of primary aggressive fibromatosis.
Patients and methods: Treatments were categorized into: surgery with or without radiotherapy and nonsurgical strategies with systemic treatment alone or wait and see policy. Eighty-nine patients had initial resection of their primary tumour followed by postoperative radiotherapy in 13 cases. Twenty-three did not undergo surgery but received systemic treatment or watch and wait policy.
Results: Median follow-up was 76 months. Overall 3 years EFS was 49%. In the univariate analysis, patients with microscopically complete surgery had a similar outcome to patients in the no-surgery group (3 years EFS of 65% and 68%, respectively). Gender, age, tumour size, treatment period and strategy (surgery versus no-surgery) were not statistically significant. Quality of resection according to margins and the tumour site were the only prognostic factors. There was a significant correlation between tumour site and quality of surgery (p=0.0002).
Conclusions: A subset of patients with extra-abdominal fibromatosis could be managed with a nonaggressive policy, as growth arrest concerned 2/3 of nonoperated patients. When surgery is finally necessary, it should be performed with the aim of achieving negative margins.
Similar articles
-
[Therapeutic options for aggressive fibromatosis].Handchir Mikrochir Plast Chir. 2008 Apr;40(2):88-93. doi: 10.1055/s-2007-965738. Handchir Mikrochir Plast Chir. 2008. PMID: 18437666 German.
-
Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution.J Surg Oncol. 2009 Dec 1;100(7):563-9. doi: 10.1002/jso.21384. J Surg Oncol. 2009. PMID: 19722232
-
Aggressive fibromatosis in children and adolescents: the Italian experience.Cancer. 2010 Jan 1;116(1):233-40. doi: 10.1002/cncr.24679. Cancer. 2010. PMID: 19950127
-
Pediatric aggressive fibromatosis: a retrospective analysis of 13 patients and review of literature.Cancer. 2005 Sep 1;104(5):1090-9. doi: 10.1002/cncr.21275. Cancer. 2005. PMID: 16015632 Review.
-
Desmoid tumors: need for an individualized approach.Expert Rev Anticancer Ther. 2009 Apr;9(4):525-35. doi: 10.1586/era.09.9. Expert Rev Anticancer Ther. 2009. PMID: 19374605 Review.
Cited by
-
Surgical Management of a Giant Desmoid Fibromatosis of Abdominal Wall With Vessels Invasion in a Young Man: A Case Report and Review of the Literature.Front Surg. 2022 Apr 11;9:851164. doi: 10.3389/fsurg.2022.851164. eCollection 2022. Front Surg. 2022. PMID: 35478728 Free PMC article.
-
Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review.Front Oncol. 2019 May 17;9:397. doi: 10.3389/fonc.2019.00397. eCollection 2019. Front Oncol. 2019. PMID: 31165043 Free PMC article. Review.
-
Single institution experience of split course radiotherapy in patients with desmoid tumors.Onco Targets Ther. 2019 Mar 7;12:1741-1748. doi: 10.2147/OTT.S189449. eCollection 2019. Onco Targets Ther. 2019. PMID: 30881028 Free PMC article.
-
Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality.Cancers (Basel). 2012 Feb 7;4(1):88-99. doi: 10.3390/cancers4010088. Cancers (Basel). 2012. PMID: 24213228 Free PMC article.
-
Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR.Oncotarget. 2018 Apr 6;9(26):18296-18308. doi: 10.18632/oncotarget.24817. eCollection 2018 Apr 6. Oncotarget. 2018. PMID: 29719606 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources